Galena Biopharma fka GALE

[MDMSCF]

You are assuming a phase 3 trial is required for approval. The 300 patient phase 2b trial with Herceptin, SO FAR must be demonstrating some signal of efficacy otherwise the IDMC would have not used the phrase "deemed not to be futile". If the combo demonstrates significant reduction in recurrences - it is possible given all the safety data for these two drugs that we could see a recommendation for marketing approval based on the phase 2b data. But then again, in Biotech investing common sense is not very common. Meaning what I see as black and white based on my common sense, often turns out to be black and blue. It is the nature of the beast.